WELWYN GARDEN CITY, England and BOSTON, January 6, 2015 /PRNewswire/ --
Heptares Therapeutics, the clinical-stage GPCR drug discovery and development company, notes that members of its senior management team will participate on panel discussions at the Boston Biotech East/West CEO Conference, which takes place at the Four Seasons Hotel, San Francisco, CA, USA on 10-11 January.
Dan Grau, Heptares' President, will moderate a panel discussion entitled "Global Entrepreneurs: Biotech Building Ex-US," from 1:20-1:50pm Eastern time on 10 January.
Malcolm Weir, Heptares' CEO, will participate on a panel entitled "Academia and Industry: Challenges and Synergies," from 1:40-2:10pm ET on 11 January.
Dr Weir and Mr Grau will also be in San Francisco during the JPMorgan Healthcare Conference from 12-15 January.
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of drug receptors linked to a wide range of human diseases. Our proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Using this approach, we have built an exciting pipeline of new medicines with the potential to transform the treatment of Alzheimer's disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com
HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;
StaR is a registered trademark in the EU and Japan.
SOURCE Heptares Therapeutics